Levosulpiride Aristo

Levosulpiride, the active ingredient in Levosulpiride Aristo, is a benzamide derivative presented as an oral tablet for oral use. It is employed in the management of certain psychiatric conditions and functional gastrointestinal disorders in adult patients. The medication acts by selectively blocking dopamine D2 receptors, which can help alleviate symptoms of psychosis and improve gastrointestinal motility.

GNH USA supplies Levosulpiride Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosulpiride is used in several psychiatric and gastrointestinal pathways. - Schizophrenia: reduces psychotic symptoms by antagonizing dopamine D2 receptors. - Depressive disorders: may improve mood symptoms when used as adjunct therapy. - Anxiety disorders: helps alleviate anxiety through dopaminergic modulation. - Functional dyspepsia: enhances gastric motility, relieving upper abdominal discomfort. - Gastroparesis: improves gastric emptying in patients with delayed gastric transit.

Levosulpiride may cause a range of adverse reactions.

Common Side Effects: - Extrapyramidal symptoms (e.g., tremor, rigidity) - Drowsiness or fatigue - Dry mouth - Weight gain - Nausea or vomiting - Diarrhea

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Severe hyperprolactinemia - Tardive dyskinesia - Seizures - Cardiac arrhythmias (QT prolongation) - Severe allergic reactions (e.g., Stevens‑Johnson syndrome)

Levosulpiride requires careful monitoring and patient education. - Monitor psychiatric status: assess symptom changes regularly. - Assess gastrointestinal function: watch for worsening dyspepsia. - Avoid abrupt discontinuation: taper under medical supervision. - Caution in hepatic impairment: consider dose adjustment if needed. - Store below 25°C: keep in the original pack, protect from moisture.

Levosulpiride can interact with several drug classes.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive dopamine blockade may increase extrapyramidal effects. - CYP450 inhibitors (e.g., ketoconazole): may raise levosulpiride plasma levels. - QT‑prolonging drugs: combined use can increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Anticholinergics: may reduce gastrointestinal prokinetic effect. - Alcohol: can enhance central nervous system depression. - Other dopamine antagonists: may potentiate side‑effects such as prolactin elevation.